La Jolla’s two main assets are Giapreza, a medication designed to increase blood pressure in patients with septic shock, and Xerava, a treatment for complicated intra-abdominal infections, according to a July 11 press release. The FDA has approved both products for adults.
The transaction is expected to finalize within 30 business days.
